|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
|
|
Karim Fizazi, MD, Ph.D.
|
| Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment.
|
|
|
|
|
|
|
|
|
|
|
|
|
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA)
|
|
Evan Yu, MD
|
| Phillip Koo and Evan Yu discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or response assessment for patients being considered for treatment with radiolabeled PSMA conjugates.
|
|
|
|
|
|
|
|
|
|
|
|
|
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Ian Davis, MBBS, PhD, FRACP, and Michael Hofman, MBBS, FRACP
Ian Davis and Michael Hofman discuss the TheraP trial with Alicia Morgans. This study showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel.
|
|
|
|
|
|
|
|
|
|
|
| A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation |
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer, an article published in European Urology. |
|
|
|
|
|
|
|
|
|
|
| Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with mCRPC |
| Karim Fizazi, MD, Ph.D. |
| Karim Fizazi presents health-related quality of life, pain, and safety outcomes in the phase 3 VISION study. The combination of 177Lu-PSMA-617 and standard of care in adults with mCRPC who were previously treated with androgen receptor pathway inhibitors and taxane chemotherapy extended overall survival, delayed radiographic progression-free survival, and was generally well-tolerated. |
|
|
|
|
|
| Treatment Options That Offer a Survival Benefit in mCRPC Discussion: The TheraP and VISION Trials |
| Silke Gillessen, MD |
| As part of the game-changing session at the European Association of Urology 2021 Annual Meeting, Silke Gillessen discussed the recently published TheraP and VISION trials. Dr. Gillessen notes that in the metastatic castration-resistant prostate cancer (mCRPC) setting, we now have several treatment options that offer a survival benefit, including abiraterone, cabazitaxel, docetaxel, enzalutamide, radium-223, sipuleucel-T, olaparib, and now 177Lu-PSMA-617. |
|
|
|
|
|
|
|
|
|
|
| TheraP Phase 2 Trial of Lu-PSMA-617 vs Cabazitaxel: Results and Contrasts to the VISION Study
|
| Michael Hofman, MBBS (Hons), FRACP, FAANMS
|
| Michael Hofman discusses the phase 2 trial of 177Lu-PSMA-617, TheraP, as well as important contrasts/differences between TheraP and VISION. 177Lu-PSMA-617 improves patient outcomes in men with mCRPC following docetaxel and androgen receptor directed therapy. 177Lu-PSMA-617 is more active than cabazitaxel in PSMA-avid disease with fewer Grade 3-4 adverse events and improved quality of life.
|
|
|
|
|
|
| Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
|
| Johann De Bono, MD, MSc, Ph.D., FRCP, FMedSci
|
| In this presentation, Johann De Bono discusses the VISION trial, a phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Adding 177Lu-PSMA-617 to safely combinable SOC in patients with mCRPC after androgen receptor pathway inhibition and chemotherapy extended overall survival and delayed radiographic disease progression. 177Lu-PSMA-617 was well tolerated. These findings support the adoption of 177Lu-PSMA-617 as a new treatment option in patients with mCRPC.
|
|
|
|
|
|
| 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel: Updated Results Including Progression-Free Survival and Patient-Reported Outcomes (TheraP ANZUP 1603)
|
| Michael Hofman, MBBS (Hons), FRACP, FAANMS
|
| Michael Hofman presents updated data from the TheraP study, including patient-reported outcomes (PROs) having now met pre-specified event targets. Although overall survival (OS) data remain immature, these updates from TheraP and ANZUP1603 continue to indicate activity, efficacy, and safety relative to cabazitaxel in men who have progressive mCRPC after docetaxel treatment.
|
|
|
|
|
|
|
|
|
|
|
|
